Table 1.
Drugs approved by FDA for treatment of the COVID-19 and three examples of resistance conferring mutations targeted by SABRes
| Drug class | Drug name | Brand name | Mechanism of action | Corresponding drug resistance conferring mutations | References |
|---|---|---|---|---|---|
| Monoclonal antibodies | Sotrovimab | Xevudy | Prevention of cell entry |
S:E340D S:E340K S:P337H |
[1, 4] |
| Tixagevimab and Cilgavimab | Evusheld | Prevention of cell entry |
S:E484A S:Q498R |
[8] | |
| Bebtelovimab | - | Prevention of cell entry |
S:K444T S:G446D S:P499R |
[6] | |
| Regdanvimab | Regikrona | Prevention of cell entry | S:N501Y | [8] | |
| Bamlanivimab and Etesevimab | - | Prevention of cell entry | S:Q493R | [8] | |
| Casirivimab and Imdevimab |
Regen-Cov/ Ronapreve |
Prevention of cell entry and viral escape |
S:G446S S:E484A |
[13] | |
| Synthetic antivirals | Remdesivir | Veklury | Inhibition of RNA polymerase |
NSP12:A97V NSP12:V557L NSP12:E802D |
[3, 14] |
| Nirmatrelvir and Ritonavir | Paxlovid | Inhibition of viral protease |
NSP5:T135I NSP5:H172Y NSP5:Q189K |
[5] | |
| Molnupiravir | - | Inhibition of RNA polymerase | NSP12:V557I | [15] |